Russell Investments Group Ltd. cut its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Rating) by 5.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,241 shares of the medical instruments supplier’s stock after selling 2,699 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.94% of Mesa Laboratories worth $12,549,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Conestoga Capital Advisors LLC boosted its stake in Mesa Laboratories by 1.3% during the 1st quarter. Conestoga Capital Advisors LLC now owns 523,571 shares of the medical instruments supplier’s stock valued at $133,448,000 after purchasing an additional 6,752 shares during the period. Royce & Associates LP increased its holdings in shares of Mesa Laboratories by 0.5% during the fourth quarter. Royce & Associates LP now owns 342,758 shares of the medical instruments supplier’s stock valued at $112,455,000 after purchasing an additional 1,553 shares during the period. Invesco Ltd. raised its stake in shares of Mesa Laboratories by 10.8% during the fourth quarter. Invesco Ltd. now owns 275,652 shares of the medical instruments supplier’s stock valued at $90,440,000 after purchasing an additional 26,821 shares in the last quarter. Principal Financial Group Inc. grew its position in Mesa Laboratories by 22.8% in the 4th quarter. Principal Financial Group Inc. now owns 90,735 shares of the medical instruments supplier’s stock valued at $29,601,000 after buying an additional 16,855 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Mesa Laboratories by 28.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 57,988 shares of the medical instruments supplier’s stock valued at $19,026,000 after buying an additional 12,894 shares in the last quarter. Institutional investors own 91.90% of the company’s stock.
Analysts Set New Price Targets
Separately, StockNews.com lowered shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research note on Friday.
Insider Buying and Selling at Mesa Laboratories
Mesa Laboratories Stock Performance
MLAB opened at $202.42 on Friday. The company has a quick ratio of 2.07, a current ratio of 2.59 and a debt-to-equity ratio of 0.55. The firm has a market cap of $1.07 billion, a PE ratio of 578.36 and a beta of 0.52. The business has a fifty day simple moving average of $202.05 and a 200-day simple moving average of $232.77. Mesa Laboratories, Inc. has a fifty-two week low of $178.32 and a fifty-two week high of $333.42.
Mesa Laboratories (NASDAQ:MLAB – Get Rating) last issued its quarterly earnings results on Tuesday, May 31st. The medical instruments supplier reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of $0.48 by ($0.82). Mesa Laboratories had a return on equity of 6.30% and a net margin of 1.01%. As a group, equities analysts predict that Mesa Laboratories, Inc. will post 7.6 EPS for the current fiscal year.
Mesa Laboratories Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 15th. Shareholders of record on Wednesday, August 31st will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.32%. The ex-dividend date of this dividend is Tuesday, August 30th. Mesa Laboratories’s payout ratio is 182.86%.
Mesa Laboratories Profile
Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries.
- Get a free copy of the StockNews.com research report on Mesa Laboratories (MLAB)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.